Dyne Therapeutics, Inc. SEC filings DYN

Dyne Therapeutics, Inc. has 796 filings in SEC EDGAR's recent list, going back to Jul 23, 2020. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Dyne Therapeutics, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Nov 17, 2021 —
CORRESP Letter to the SEC Nov 15, 2021 —
UPLOAD Letter from the SEC Nov 10, 2021 —
EFFECT Filing Jan 20, 2021 —
CORRESP Letter to the SEC Jan 19, 2021 —
CORRESP Letter to the SEC Jan 19, 2021 —
UPLOAD Letter from the SEC Jan 13, 2021 —
DRS Filing Jan 11, 2021 —
EFFECT Filing Sep 16, 2020 —
CERT Filing Sep 16, 2020 —
CORRESP Letter to the SEC Sep 14, 2020 —
CORRESP Letter to the SEC Sep 14, 2020 —
8-A12B Filing Sep 11, 2020 —
UPLOAD Letter from the SEC Sep 10, 2020 —
CORRESP Letter to the SEC Sep 10, 2020 —
CORRESP Letter to the SEC Aug 25, 2020 —
UPLOAD Letter from the SEC Aug 20, 2020 —
D Filing Aug 14, 2020 —
DRS Filing Jul 23, 2020 —

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DYN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
Large accelerated filer
SEC CIK
1818794

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.